Oncology Programs

Need Information?


LADR™ Technology Platform

Our innovative LADR™ (Linker Activated Drug Release) technology employs a broad portfolio of novel linker molecules that selectively bind to circulating albumin and have the ability to be linked to a wide variety of anti-cancer payloads. Our research efforts currently center on creating new molecules from the combination of ultra-high potency cytotoxic payloads with tunable linkers. The molecules that we are currently evaluating concentrate at the tumor site providing targeted delivery of the chemotherapeutic payloads.

As a result of the determined efforts of our world-class scientists at our laboratory in Freiburg, Germany, we recently announced the nomination of DK049 as our next clinical candidate.

View more information on DK049.

View 2016 AACR Annual Meeting LADR™ Poster (PDF)